This is because high SLC7A11 expression can increase the concentration of specific metabolites in tumour cells, such as GSH, which inhibits the activation of immune cells and the apoptosis of tumour cells, thereby reducing the efficacy of immune therapy13. The gene discussed is SLC7A11; the disease is neoplasm.